Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
TNF Inhibitors
•
Dermatology
How do you approach management of patients with RA who have paradoxical eczematous reaction while on TNF inhibitor?
What alternative biologics would be preferred?
Related Questions
What is your approach to diagnosing and managing methotrexate-induced alopecia?
What biologics would you use in a patient with rheumatoid arthritis who developed multiple basal cell carcinomas requiring Mohs surgery while on a TNF-inhibitor and did not respond to rituximab?
Would you be hesitant to continue a TNF inhibitor in a patient with stable RA and a history of COPD, Cor Pulmonale, severe reduced RVEF, but LVEF 65%?
Is it safe to use one TNF inhibitor (e.g., infliximab) in a patient who has had a severe allergic reaction to a different TNF inhibitor (e.g., adalimumab)?
How do you approach management of RA in patients who have developed anti-drug antibodies to infliximab, especially if use of methotrexate is contraindicated and patients have tried and failed several other biologics?
Would you consider prescribing a JAK inhibitor for a patient with a history of DVT who is on chronic anticoagulation, or would the thrombotic risk deter you?
How do you manage recalcitrant tumid lupus in a patient with partial response to antimalarials and off-label apremilast, in the setting of coexisting MDS with significant neutropenia?
Would you stop methotrexate or leflunomide if MCV increases after starting the medication with no other parameters of anemia or leukopenia?
What are useful clinical features that help differentiate mechanics hands from other conditions such as hand dermatitis or psoriasis?
In a patient with a history of seropositive erosive RA who has undergone treatment for a periprosthetic joint infection and currently has an antibiotic spacer in place with clinical improvement, what is the appropriate timing and strategy for restarting DMARDs and/or biologic therapy to balance infection risk with RA disease control?